Combining MK626, a Novel DPP-4 Inhibitor, and Low-Dose Monoclonal CD3 Antibody for Stable Remission of New-Onset Diabetes in Mice-Reference-Cited by-同舟云学术

Combining MK626, a Novel DPP-4 Inhibitor, and Low-Dose Monoclonal CD3 Antibody for Stable Remission of New-Onset Diabetes in Mice

Published:2014-09-30 Issue:9 Volume:9 Page:e107935
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ding Lei,Gysemans Conny A.,Stangé Geert,Heremans Yves,Yuchi Yixing,Takiishi Tatiana,Korf Hannelie,Chintinne Marie,Carr Richard D.,Heimberg Harry,Pipeleers Daniel,Mathieu Chantal

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders;KC Herold;Diabetes,2013

2. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes;KC Herold;Diabetes,2005

3. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus;KC Herold;N Engl J Med,2002

4. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes;B Keymeulen;N Engl J Med,2005

5. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass;B Keymeulen;Diabetologia,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis;Journal of International Medical Research;2021-12

2. Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice;International Immunopharmacology;2020-11

3. GLP-1R is downregulated in beta cells of NOD mice and T1D patients;2019-11-17

4. CD26 in autoimmune diseases: The other side of “moonlight protein”;International Immunopharmacology;2019-10

5. Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun;World Journal of Diabetes;2019-04-15